DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMD

Information source: Shahid Beheshti Medical University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Neovascular Age-Related Macular Degeneration

Intervention: bevacizumab (Drug); bevacizumab + triamcinolone acetonide (Drug)

Phase: Phase 3

Status: Active, not recruiting

Sponsored by: Shahid Beheshti Medical University

Official(s) and/or principal investigator(s):
Hamid Ahmadieh, MD, Principal Investigator, Affiliation: Ophthalmic Research Center of Shaheed Beheshti Medical University

Summary

To compare the efficacy and safety results of intravitreal bevacizumab alone with bevacizumab + triamcinolone acetonide in neovascular AMD.

Clinical Details

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Primary outcome: visual acuity

Secondary outcome:

central macular thickness

leakage in fluorescein angiography

intraocular pressure

anterior chamber reaction

Eligibility

Minimum age: 50 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Cases of active neovascular AMD with visual acuity of 20/400- 20/40

Exclusion Criteria:

- History of glaucoma or ocular hypertension

- Disciform scar

Locations and Contacts

Hamid Ahmadieh, MD, Tehran 16666, Iran, Islamic Republic of
Additional Information

Starting date: November 2005
Last updated: June 25, 2008

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017